PMID- 28536852
OWN - NLM
STAT- MEDLINE
DCOM- 20180712
LR  - 20181202
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Jun
TI  - The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving 
      Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease.
PG  - 311-318
LID - 10.1007/s10557-017-6729-y [doi]
AB  - The optimal treatment approach to patients with coronary artery disease (CAD), 
      including those with type 2 diabetes mellitus (T2DM), has been extensively 
      evaluated. Several trials of stable ischemic heart disease including patients 
      with T2DM have demonstrated that medical management is comparable to 
      revascularization in terms of mortality and rates of major adverse cardiovascular 
      events (MACE). There has been a growing appreciation for optimal medical 
      therapy's (OMT) role in improving clinical outcomes. It is vital to target T2DM 
      patients to prevent or delay MACE events through advanced OMT, ultimately 
      delaying if not avoiding the need for revascularization. There has been 
      significant evolution in the development of pharmacologic management of T2DM 
      patients. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new 
      pharmacologic therapy with tremendous potential to alter clinical practice and 
      influence practice guidelines. SGLT2-inhibitors have great potential in reducing 
      MACE in patients with T2DM and CAD. Empagliflozin should be considered as a part 
      of OMT among these patients. If results similar to the EMPA-REG OUTCOMES trial 
      are replicated in other trials, the use of these pharmacologic agents as a part 
      of OMT may narrow the gap between revascularization and OMT alone in patients 
      with T2DM and multi-vessel disease. Future studies on the role of SLGT-2 
      inhibitors with regard to heart failure outcomes are needed to elucidate the 
      mechanisms and clinical effects in this vulnerable population.
FAU - Mosleh, Wassim
AU  - Mosleh W
AD  - University at Buffalo, State University of New York, Buffalo, NY, USA.
FAU - Sharma, Abhinav
AU  - Sharma A
AD  - Duke Clinical Research Institute, Duke University, Durham, NC, USA.
FAU - Sidhu, Mandeep S
AU  - Sidhu MS
AD  - Department of Medicine, Albany Medical College, Albany Medical Center, Albany, 
      NY, USA.
FAU - Page, Brian
AU  - Page B
AD  - University at Buffalo, State University of New York, Buffalo, NY, USA.
FAU - Sharma, Umesh C
AU  - Sharma UC
AD  - University at Buffalo, State University of New York, Buffalo, NY, USA.
FAU - Farkouh, Michael E
AU  - Farkouh ME
AD  - Peter Munk Cardiac Centre, University Health Network, 585 University Avenue, 
      4N474, Toronto, ON, M5G 2N2, Canada. michael.farkouh@uhn.ca.
AD  - The Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular 
      Research, University of Toronto, Toronto, ON, Canada. michael.farkouh@uhn.ca.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cardiovascular System/*drug effects
MH  - Coronary Artery Disease/*drug therapy
MH  - Diabetes Mellitus, Type 2
MH  - Humans
MH  - *Sodium-Glucose Transporter 2 Inhibitors
OTO - NOTNLM
OT  - Coronary artery disease
OT  - Diabetes mellitus
OT  - Optimal medical therapy
OT  - Outcomes
OT  - SGLT2 inhibitors
EDAT- 2017/05/26 06:00
MHDA- 2018/07/13 06:00
CRDT- 2017/05/25 06:00
PHST- 2017/05/26 06:00 [pubmed]
PHST- 2018/07/13 06:00 [medline]
PHST- 2017/05/25 06:00 [entrez]
AID - 10.1007/s10557-017-6729-y [pii]
AID - 10.1007/s10557-017-6729-y [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2017 Jun;31(3):311-318. doi: 10.1007/s10557-017-6729-y.